Angiotech Selects Independent Sales Rep in Japan for Contour Threads(TM) Product Line
20 Juli 2006 - 3:30PM
PR Newswire (US)
Expanding Markets for Innovative, Minimally-Invasive Facelift
Product VANCOUVER, July 20 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced that it has signed an agreement with KMT Japan to sell
Angiotech's Contour Threads(TM) product line in Japan, which is the
ninth largest aesthetics market worldwide according to the
International Society of Aesthetic Plastic Surgery (ISAPS). These
top ten countries combined perform approximately 68% of all global
aesthetic procedures. "We continue to expand our reach in the
growing Asia-Pacific market with this new distribution agreement.
For the first time, people in Japan will have the option of a
minimally-invasive facelift procedure performed with Contour
Threads products," said Dr. William Hunter, President and Chief
Executive Officer of Angiotech. To support the introduction of the
Contour Thread product line in Japan, Angiotech held an initial
training course which included a number of Japanese plastic and
facial plastic surgeons, including Dr. Taturo Kamakura, who is one
of the top cosmetic and aesthetic surgeons in Japan and founder of
the Seishin Cosmetic Clinics, found in major cities across Japan.
These eight physicians will act as the core Center of Excellence
(COE) Training Instructors in Japan. It is expected that
approximately 50 physicians will be trained and performing
procedures with Contour Threads products by the end of this year in
Japan. Over 2,400 physicians worldwide have been trained to perform
procedures with Contour Threads. Under the terms of the agreement,
KMT Japan must meet minimum quarterly sales volume commitments
during the first year of the agreement, which runs through 2008.
The agreement's structure allows for Angiotech to enter this new
market at a relatively low cost base and brings the advantage of
building and maintaining a solid base of customer contacts. The
global market for aesthetics procedures generated over $15 billion
in 2004 and is growing according to a study by Medical Insight,
Inc. Angiotech continues to build momentum in global markets and
has more than doubled the number of international distribution and
independent sales agreements in place compared to this time last
year. Angiotech believes that facelift procedures performed with
Contour Threads products could increase the aesthetic procedure
market by offering a cost-effective, minimally invasive alternative
to the traditional facelift procedure. Doctors and patients alike
are interested in the innovative procedure that can be performed in
a doctor's office with no general anaesthesia and very little "down
time" for patients. A procedure performed with the Contour Threads
product is an increasingly attractive option for people looking for
a refreshed, but not extreme change, which gives them subtle and
natural-looking results. Further Opportunities for the Contour
Threads Product Line Unlike traditional sutures, the Contour
Threads product line's patented technology enables surgical sutures
to self-anchor and suspend sagging tissue without the need for
suture knots. Building on the success of the minimally-invasive
facelift procedure, Angiotech is exploring other potential
indications of the Contour Threads product line for "non-extreme"
aesthetic procedures, such as breast lifts, neck contouring, and
other body contouring indications. The Contour Threads product line
allows Angiotech to expand this market to include those patients
who desire aesthetic changes but are unwilling to have more
invasive procedures, such as implant surgery. It is anticipated
that the same technology used in the Contour Threads product will
be adapted for general wound closure in orthopaedic, cosmetic,
vascular, and endoscopic surgery. Eliminating knot-tying saves
time, minimizes the risk of infection, and reduces wound leakage.
Angiotech will also continue to develop its portfolio of
next-generation Contour Threads products, including a biodegradable
version, which will be absorbed safely and relatively quickly in
the body. To learn more about the Contour Threads product, please
visit: http://www.contourthreads.com/ About Angiotech
Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a global
specialty pharmaceutical and medical device company with 14
facilities in 6 countries and over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Note on Forward Looking Statement:
Statements contained in this press release or in our other written
or oral public communications that are not based on historical or
current fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Such forward-looking statements are based
on assumptions that involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Forward-looking statements in this release include the
statements regarding; any potential financial benefits to Angiotech
to be realized from the transaction, the ability of Angiotech to
find other potential uses for the Contour Threads product line, the
ability to develop and commercialize any new products, the accuracy
of information concerning the numbers of physicians who have been
trained or have performed procedures using Contour Threads, and the
accuracy of information concerning the size of the global aesthetic
procedures market. These statements are also subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. These risks and uncertainties include, among
others; the timing of and safety and efficacy results from clinical
trials and decisions made by Angiotech based on these results, the
ability to obtain regulatory approval to develop and commercialize
new products, the ability to manufacture sufficient quantities of
product for development and commercialization activities and to do
so in a timely and cost efficient manner, decisions by regulatory
authorities related to the development and commercialization of
potential products, the competitive environment for such products,
the availability of resources and funding, and the risks and
uncertainties associated with the business and described in
Angiotech's filings with the United States Securities and Exchange
Commission or the Canadian securities regulators. The forward
looking statements are also based on a number of assumptions,
including; that other uses for the Contour Threads product line
exist, that any products or therapies identified and developed by
Angiotech will be able to obtain regulatory approval, that funding
and resources for research and development will be available, and
that there will be a market for any products successfully developed
by Angiotech. Given these uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. Angiotech(R) and Contour Threads(TM)
are trademarks of Angiotech Pharmaceuticals, Inc. and its
subsidiaries. All rights reserved. CONTACT: Analysts and
Institutional Investors: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (416)
997-9006, ; Media and Retail Investors: Jodi Regts, Manager,
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604)
221-7930, DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT:
Analysts and Institutional Investors: Janet Craig, VP, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (416) 997-9006, ; Media and Retail Investors: Jodi Regts,
Manager, Corporate Communications, Angiotech Pharmaceuticals, Inc.,
(604) 221-7930,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024